Oncotarget

Research Papers:

Expression of PD-1/PD-L1 and PD-L2 in peripheral T-cells from non-small cell lung cancer patients

Oscar Arrieta _, Edgar Montes-Servín, Juan-Manuel Hernandez-Martinez, Andrés F. Cardona, Eibar Casas-Ruiz, José C. Crispín, Daniel Motola, Diana Flores-Estrada and Lourdes Barrera

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2017; 8:101994-102005. https://doi.org/10.18632/oncotarget.22025

Metrics: PDF 1932 views  |   HTML 2601 views  |   ?  


Abstract

Oscar Arrieta1,*, Edgar Montes-Servín1,*, Juan-Manuel Hernandez-Martinez1,2,*, Andrés F. Cardona3, Eibar Casas-Ruiz1, José C. Crispín4, Daniel Motola5, Diana Flores-Estrada1 and Lourdes Barrera1

1Functional Unit of Thoracic Oncology and Laboratory of Personalized Medicine, Instituto Nacional de Cancerología, Mexico City, Mexico

2CONACyT-Instituto Nacional de Cancerología, Mexico City, Mexico

3Clinical and Translational Oncology Group, Institute of Oncology, Clínica del Country, Bogotá, Colombia

4Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico

5Centro Oncológico, Hospital Médica Sur, Mexico City, Mexico

*These authors have contributed equally to this work

Correspondence to:

Oscar Arrieta, email: ogar@unam.mx

Keywords: immunotherapy; checkpoint inhibitors; lung adenocarcinoma; prognosis; circulating lymphocytes

Received: August 06, 2017    Accepted: September 03, 2017    Published: October 24, 2017

ABSTRACT

Binding of programmed death-1 (PD-1) with its ligands (PD-L1/2) transmits a co-inhibitory signal in activated T-cells that promotes T-cell exhaustion, leading to tumor immune evasion. The efficacy of antibodies targeting PD-1 and PD-L1 has led to a paradigm shift in lung cancer treatment but the prognostic and predictive value of tumor PD-L1 expression remains controversial. Evaluating PD-1, PD-L1/2 expression in peripheral blood cells may serve as a potential biomarker for prognosis and response to therapy. In this prospective observational study, plasma cytokine levels and PD-1, PD-L1 and PD-L2 expression was evaluated in circulating CD3+, CD3+CD4+ and CD3+CD8+ cells from 70 treatment-naïve patients with advanced NSCLC (Stage IIIB and IV) and from 10 healthy donors. The primary objective was to assess OS according to PD-1, PD-L1, PD-L2 expression status on PBMCs and lymphocyte subsets. Our results indicate that the percentage of PD-L1+CD3+, PD-L1+CD3+CD8+ PD-L2+PBMCs, PD-L2+CD3+, PD-L2+CD3+CD4+ cells was higher in patients than in healthy donors. Survival was decreased among patients with a high percentage of either PD-1+PBMCs, PD-1+CD3+, PD-L1+CD3+, PD-L1+CD3+CD8+, PD-L2+CD3+, PD-L2+CD3+CD4+, or PD-L2+CD3+CD8+ cells. IL-2 and TNF-α showed the strongest association with PD-L1 and PD-L2 expression on specific subsets of T-lymphocytes. Our findings suggest that increased PD-1/PD-L1/PDL-2 expression in PBMCs, particularly in T-cells, may be an additional mechanism leading to tumor escape from immune control. This study is registered with ClinicalTrials.gov, number NCT02758314.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 22025